The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations

Journal of Clinical Investigation

Volumn 103, Issue 3, 1999, Pages 355-363

  Vaishnaw, Akshay K ^a   Orlinick, Jason R ^a   Chu, Jia Li ^a   Krammer, Peter H ^b   Chao, Moses V ^c   Elkon, Keith B ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; AUTOIMMUNITY; AUTOSOMAL DOMINANT INHERITANCE; CELL CULTURE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; PATIENT REFERRAL; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR GENE;

EID: 0032931219     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5121     Document Type: Article

References (44)

1. Orlinick, J.R., Vaishnaw, A.K, Elkon, K.B., and Chao, M.V. 1997. Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J. Biol. Chem. 272:28889-28894.
2. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355-365.
3. Chinnaiyan, A.M., O'Rourke, K., Tewari, M., and Dixit, V.M. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:505-512.
4. Boldin, M.P., et al. 1995. A novel protein that interacts with the death domain of Fas/Apo-1 contains a sequence motif related to the death domain. J. Biol. Chem. 270:7795-7798.
5. Salvesen, G.S., and Dixit, V.M. 1997. Caspases: intracellular signaling by proteolysis. Cell 14:443-446.
6. Tepper, C.G., et al. 1995. Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc. Natl. Acad. Sci. USA. 92:8443-8447.
7. Cifone, M.G., et al. 1994. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J. Exp. Med. 177:1547-1552.
8. Santana, P., et al. 1996. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 86:189-199.
9. Yang, X., Khosravi-Far, R., Chang, H.Y., and Baltimore, D. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 89:1067-1076.
10. Kennedy, N.J., and Budd, R.C. 1998. Phosphorylation of FADD/MORT1 and Fas by kinases that associate with the membrane-proximal cytoplasmic domain of Fas. J. Immunol. 160:4881-4888.
11. Russell, J.H., Rush, B., Weaver, C., and Wang, R. 1993. Mature Tcells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA. 90:4409-4413.
12. Singer, G.G., and Abbas, A.K. 1994. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in Tcell receptor transgenic mice. Immunity. 1:365-371.
13. Rathmell, J.C., Townsend, S.E., Xu, J.C., Flavell, R.A., and Goodnow, C.C. 1996. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell. 57:319-329.
14. Cohen, P.L., and Eisenberg, R.A. 1991. lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243-269.
15. Canale, V.C., and Smith, H.C. 1967. Chronic lymphadenopathy simulating malignant lymphoma. J. Pediatr. 70:891-899.
16. Drappa J., Vaishnaw, A.K., Sullivan, K.E., Chu, J.L., and Elkon, K.B. 1996. The Canale Smith syndrome: an inherited autoimmune disorder associated with defective lymphocyte apoptosis and mutations in the Fas gene. N. Engl. J. Med. 335:1643-1649.
17. Sneller, M.G., et al. 1992. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin. Invest. 90:334-341.
18. Rieux-Laucat, F., et al. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1347-1349.
19. Fisher, G.H., et al. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell. 81:935-946.
20. Dianzani, U., et al. 1997. Deficiency of the Fas pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood. 89:2871-2879.
21. Bettinardi, A., et al. 1997. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood. 89:902-909.
22. Sneller, M.C., et al. 1997. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 89:1341-1348.
23. Pensati, L., et al. 1997. Fas/Apol mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology. 113:1384-1389.
24. Kasahara, Y., et al. 1998. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int. Immunol. 10:195-202.
25. Rao, L. M., Shahidi, N.T., and Opitz, J.M. 1974. Hereditary splenomegaly with hypersplenism. Clin. Genet. 5:379-386.
26. Trauth, B. C., et al. 1989. Monoclonal antibody-mediated tumor regression by apoptosis. Science. 245:301-305.
27. Van Lopik, T., et al. 1999. SLE patients wirh high plasma levels of sFas are at risk for developing a relapse. J Rheumatol. In press.
28. Chu, J.L., et al. 1995. Massive upregulation of the Fas ligand in lpr and gld mice. J. Exp. Med. 181:393-398.
29. Orlinick, J.R., Elkon, K.B., and Chao, M.V. 1997. Separate domains of the human Fas ligand dictate self-association and receptor binding. J. Biol. Chem. 272:32221-32229.
30. Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., and Krammer, P.H. 1995. Autocrine T cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438-441.
31. Huang, B., Eberstadt, M., Olejniczak, E., Meadows, R., and Fesik, S. 1996. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature. 384:638-641.
32. Cascino, I., Fiucci, G., Papoff, G., and Ruberti, G. 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:2706-2713.
33. Boldin, M.P., Goncharov, T.M., Goltsev, Y.V., and Wallach, D. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1 and TNF receptor-induced cell death. Cell. 85:803-815.
34. Muzio, M., et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:817-827.
35. Vincenz, C., and Dixit, V.M. 1997. Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J. Biol. Chem. 7:6578-6583.
36. O'Neil, K.T., and DeGrado, W.F. 1990. A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science. 250:646-651.
37. Chakrabartry, A., Schellman, J.A., and Baldwin, R.L. 1991. Large differences in the helix propensities of alanine and glycine. Nature. 351:586-588.
38. Zhang, J., Cado, D., Chen, A., Kabra, N.H., and Winoto, A. 1998. Fasmediated apoptosis and activation-induced T cell proliferation are defective in mice lacking FADD/Mort1. Nature. 392:296-300.
39. Newton, K., Harris, A.W., Bath, M.L., Smith, K.G.C., and Strasser, A. 1998. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO, J. 17:706-718.
40. Fadeel, B., Lindberg, J., Achour, A., and Chiodi, F. 1998. A three-dimensional model of the Fas/Apo-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites. Int. Immunol. 10:131-140.
41. Matsuzawa, A., Kimura, M., Muraiso, T., Kominami, R., and Katagiri, T. 1991. Genotype-restricted lymphoproliferation in autoimmune lpr mice. Eur. J. Immunol. 21:1535-1542.
42. cg and gld genes is of lpr but not of gld phenotype. Eur. J. Immunol. 24:1714-1716.
43. cg in the heterozygous state on different genetic backgrounds. Cell. Immunol. 148:91-102.
44. Alderson, M.R., et al. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178:2231-2235.